

Complex Injectables

our commitment to
advanced solutions



 **bluepharma**

IMPROVED
DRUG
STABILITY



TARGETED
DELIVERY


LOWER
TOXICITY



ENHANCED
BIOAVAILABILITY

1. Our approach - Liposomes

Bluepharma's approach to Complex Injectables makes use of vesicles composed of one or more lipid membranes, called liposomes, capable of entrapping both hydrophilic and hydrophobic drugs.



2. Why Liposomes?

Technology benefits	<ul style="list-style-type: none">• Targeted delivery• Modified release• Enhanced bioavailability, PK/PD• Lower toxicity
Overcoming formulation challenges	<ul style="list-style-type: none">• Suitable for water- and lipid-soluble APIs• Improved drug stability

3. Our developments:

Amphotericin B (Ambisome®)	<ul style="list-style-type: none">• First-line against some fungal infections• Improved Safety• Orphan drug
Bupivacaine (Exparel®)	<ul style="list-style-type: none">• Postsurgical analgesic• Long acting (72h)• Single dose• Less side effects in comparison to conventional dosage forms and opioids
Doxorubicin (Doxil®)	<ul style="list-style-type: none">• Ovarian cancer and others• Improved safety• Orphan drug
Irinotecan (Onivyde®)	<ul style="list-style-type: none">• Metastatic pancreatic adenocarcinoma• Improved PK/ PD and safety• Orphan drug